Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis

Jose L. Porras, Wuyang Yang, Tomas Garzon-Muvdi, Risheng Xu, Jaishri Blakeley, Allan Belzberg, Justin M. Caplan, Syed Khalid, Geoffrey P. Colby, Alexander L. Coon, Rafael J. Tamargo, Edward S. Ahn, Judy Huang

Research output: Contribution to journalArticle

Abstract

Introduction The current study describes the impact of surgery in preventing follow-up ipsilateral transient ischemic attacks (TIAs)/strokes in an East Coast North American cohort of patients with both moyamoya syndrome (MMS) and neurofibromatosis type 1 (NF1) (MMS-NF1). Methods We retrospectively reviewed records of patients with MMS and NF1 at the Johns Hopkins Medical Institutions from 1990–2014. Baseline characteristics and follow-up results including subsequent ipsilateral strokes were collected and compared between a revascularization group (group 1) and a conservatively managed group (group 2) on a per-hemisphere basis. Results A total of 9 patients (14 hemispheres) were included in our study. The average age of all patients at NF1 diagnosis was 2.1 ± 7.7 years, with 6 being female (66.7%). The average age of all patients at MMS diagnosis was 10.4 ± 16.6 years with the median age being 7.7 years (range: 4.1–27.0 years). Race distribution was: White (n = 4, 44.4%), Black (n = 3, 33.3%), and Asian (n = 2, 22.2%). Four patients (44.5%) experienced cerebrovascular manifestations of MMS before MMS diagnosis. Group 1 was younger at MMS diagnosis (P = 0.009), likely with a more acute symptom onset (P = 0.077). Management strategies were: pial synangiosis (n = 3, 21.4%) and conservative (n = 11, 78.6%). During an average follow-up period of 6.28 ± 2.0 years, no ipsilateral TIAs/strokes were observed for group 1; conversely, 2 ipsilateral TIAs (18.2%) and 2 ipsilateral strokes (18.2%) occurred in group 2. Conclusions In our study of non-Asian patients with MMS-NF1, revascularization reduced stroke recurrence and deterioration of symptoms. However, more studies are warranted to further explore the role of revascularization procedures given the rarity of this disease combination.

Original languageEnglish (US)
Pages (from-to)19-25
Number of pages7
JournalWorld Neurosurgery
Volume99
DOIs
StatePublished - Mar 1 2017

Fingerprint

Moyamoya Disease
Neurofibromatosis 1
Transient Ischemic Attack
Recurrence

Keywords

  • Moyamoya
  • Neurofibromatosis 1
  • Revascularization
  • Stroke

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis. / Porras, Jose L.; Yang, Wuyang; Garzon-Muvdi, Tomas; Xu, Risheng; Blakeley, Jaishri; Belzberg, Allan; Caplan, Justin M.; Khalid, Syed; Colby, Geoffrey P.; Coon, Alexander L.; Tamargo, Rafael J.; Ahn, Edward S.; Huang, Judy.

In: World Neurosurgery, Vol. 99, 01.03.2017, p. 19-25.

Research output: Contribution to journalArticle

Porras, Jose L.; Yang, Wuyang; Garzon-Muvdi, Tomas; Xu, Risheng; Blakeley, Jaishri; Belzberg, Allan; Caplan, Justin M.; Khalid, Syed; Colby, Geoffrey P.; Coon, Alexander L.; Tamargo, Rafael J.; Ahn, Edward S.; Huang, Judy / Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis.

In: World Neurosurgery, Vol. 99, 01.03.2017, p. 19-25.

Research output: Contribution to journalArticle

@article{1d16614f358249659c9eeab15b38bdc2,
title = "Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis",
abstract = "Introduction The current study describes the impact of surgery in preventing follow-up ipsilateral transient ischemic attacks (TIAs)/strokes in an East Coast North American cohort of patients with both moyamoya syndrome (MMS) and neurofibromatosis type 1 (NF1) (MMS-NF1). Methods We retrospectively reviewed records of patients with MMS and NF1 at the Johns Hopkins Medical Institutions from 1990–2014. Baseline characteristics and follow-up results including subsequent ipsilateral strokes were collected and compared between a revascularization group (group 1) and a conservatively managed group (group 2) on a per-hemisphere basis. Results A total of 9 patients (14 hemispheres) were included in our study. The average age of all patients at NF1 diagnosis was 2.1 ± 7.7 years, with 6 being female (66.7%). The average age of all patients at MMS diagnosis was 10.4 ± 16.6 years with the median age being 7.7 years (range: 4.1–27.0 years). Race distribution was: White (n = 4, 44.4%), Black (n = 3, 33.3%), and Asian (n = 2, 22.2%). Four patients (44.5%) experienced cerebrovascular manifestations of MMS before MMS diagnosis. Group 1 was younger at MMS diagnosis (P = 0.009), likely with a more acute symptom onset (P = 0.077). Management strategies were: pial synangiosis (n = 3, 21.4%) and conservative (n = 11, 78.6%). During an average follow-up period of 6.28 ± 2.0 years, no ipsilateral TIAs/strokes were observed for group 1; conversely, 2 ipsilateral TIAs (18.2%) and 2 ipsilateral strokes (18.2%) occurred in group 2. Conclusions In our study of non-Asian patients with MMS-NF1, revascularization reduced stroke recurrence and deterioration of symptoms. However, more studies are warranted to further explore the role of revascularization procedures given the rarity of this disease combination.",
keywords = "Moyamoya, Neurofibromatosis 1, Revascularization, Stroke",
author = "Porras, {Jose L.} and Wuyang Yang and Tomas Garzon-Muvdi and Risheng Xu and Jaishri Blakeley and Allan Belzberg and Caplan, {Justin M.} and Syed Khalid and Colby, {Geoffrey P.} and Coon, {Alexander L.} and Tamargo, {Rafael J.} and Ahn, {Edward S.} and Judy Huang",
year = "2017",
month = "3",
doi = "10.1016/j.wneu.2016.11.051",
volume = "99",
pages = "19--25",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis

AU - Porras,Jose L.

AU - Yang,Wuyang

AU - Garzon-Muvdi,Tomas

AU - Xu,Risheng

AU - Blakeley,Jaishri

AU - Belzberg,Allan

AU - Caplan,Justin M.

AU - Khalid,Syed

AU - Colby,Geoffrey P.

AU - Coon,Alexander L.

AU - Tamargo,Rafael J.

AU - Ahn,Edward S.

AU - Huang,Judy

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Introduction The current study describes the impact of surgery in preventing follow-up ipsilateral transient ischemic attacks (TIAs)/strokes in an East Coast North American cohort of patients with both moyamoya syndrome (MMS) and neurofibromatosis type 1 (NF1) (MMS-NF1). Methods We retrospectively reviewed records of patients with MMS and NF1 at the Johns Hopkins Medical Institutions from 1990–2014. Baseline characteristics and follow-up results including subsequent ipsilateral strokes were collected and compared between a revascularization group (group 1) and a conservatively managed group (group 2) on a per-hemisphere basis. Results A total of 9 patients (14 hemispheres) were included in our study. The average age of all patients at NF1 diagnosis was 2.1 ± 7.7 years, with 6 being female (66.7%). The average age of all patients at MMS diagnosis was 10.4 ± 16.6 years with the median age being 7.7 years (range: 4.1–27.0 years). Race distribution was: White (n = 4, 44.4%), Black (n = 3, 33.3%), and Asian (n = 2, 22.2%). Four patients (44.5%) experienced cerebrovascular manifestations of MMS before MMS diagnosis. Group 1 was younger at MMS diagnosis (P = 0.009), likely with a more acute symptom onset (P = 0.077). Management strategies were: pial synangiosis (n = 3, 21.4%) and conservative (n = 11, 78.6%). During an average follow-up period of 6.28 ± 2.0 years, no ipsilateral TIAs/strokes were observed for group 1; conversely, 2 ipsilateral TIAs (18.2%) and 2 ipsilateral strokes (18.2%) occurred in group 2. Conclusions In our study of non-Asian patients with MMS-NF1, revascularization reduced stroke recurrence and deterioration of symptoms. However, more studies are warranted to further explore the role of revascularization procedures given the rarity of this disease combination.

AB - Introduction The current study describes the impact of surgery in preventing follow-up ipsilateral transient ischemic attacks (TIAs)/strokes in an East Coast North American cohort of patients with both moyamoya syndrome (MMS) and neurofibromatosis type 1 (NF1) (MMS-NF1). Methods We retrospectively reviewed records of patients with MMS and NF1 at the Johns Hopkins Medical Institutions from 1990–2014. Baseline characteristics and follow-up results including subsequent ipsilateral strokes were collected and compared between a revascularization group (group 1) and a conservatively managed group (group 2) on a per-hemisphere basis. Results A total of 9 patients (14 hemispheres) were included in our study. The average age of all patients at NF1 diagnosis was 2.1 ± 7.7 years, with 6 being female (66.7%). The average age of all patients at MMS diagnosis was 10.4 ± 16.6 years with the median age being 7.7 years (range: 4.1–27.0 years). Race distribution was: White (n = 4, 44.4%), Black (n = 3, 33.3%), and Asian (n = 2, 22.2%). Four patients (44.5%) experienced cerebrovascular manifestations of MMS before MMS diagnosis. Group 1 was younger at MMS diagnosis (P = 0.009), likely with a more acute symptom onset (P = 0.077). Management strategies were: pial synangiosis (n = 3, 21.4%) and conservative (n = 11, 78.6%). During an average follow-up period of 6.28 ± 2.0 years, no ipsilateral TIAs/strokes were observed for group 1; conversely, 2 ipsilateral TIAs (18.2%) and 2 ipsilateral strokes (18.2%) occurred in group 2. Conclusions In our study of non-Asian patients with MMS-NF1, revascularization reduced stroke recurrence and deterioration of symptoms. However, more studies are warranted to further explore the role of revascularization procedures given the rarity of this disease combination.

KW - Moyamoya

KW - Neurofibromatosis 1

KW - Revascularization

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85006341624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006341624&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2016.11.051

DO - 10.1016/j.wneu.2016.11.051

M3 - Article

VL - 99

SP - 19

EP - 25

JO - World Neurosurgery

T2 - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -